Adimmune’s November Revenue Reflects 164% Growth

Adimmune Corporation (TPE: 4142) today announced that its November revenue reached TWD210 million, reflecting year-to-year growth of 164.60%. The cumulative revenue for January-November was TWD1.587 billion, seeing a year-to-year decrease of 8.85%. The increased export of quadrivalent influenza vaccine to Mainland China, Thailand, Russia, the U.S., and the U.K. significantly boosted the revenue for the month. 

It is now the influenza season for the northern hemisphere. Since mid-November, Taiwan’s government has moved into the second phase of the influenza vaccine program offering free shots for people 50-64 years of age without high-risk chronic diseases. According to the Central Epidemic Command Center, more than 5.1 million doses of influenza vaccines have been administered this year. Adimmune suggests that a minimum seven-day interval be observed between the administration of Covid-19 vaccine and influenza vaccine.